# Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

> **NCT02993159** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 100 (actual)

## Conditions studied

- Ductal Breast Carcinoma In Situ
- Estrogen Receptor Positive

## Interventions

- **DRUG:** Afimoxifene
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo
- **OTHER:** Placebo
- **DRUG:** Tamoxifen Citrate

## Key facts

- **NCT ID:** NCT02993159
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-31
- **Primary completion:** 2021-03-30
- **Final completion:** 2022-01-24
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-12-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02993159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02993159, "Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02993159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*